Last updated on May 2020

Study of Zanubrutinib (BGB-3111) in Patients With Marginal Zone Lymphoma

Brief description of study

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).

Detailed Study Description

This is a Phase 2, open-label study of zanubrutinib in approximately 65 patients with R/R MZL. The study will evaluate efficacy, as measured by overall response rate, safety and tolerability.

Clinical Study Identifier: NCT03846427

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.